Retatrutide targets three metabolic pathways simultaneously, delivering up to 24% body weight reduction in clinical trials.
2,400+ people already on the waitlist
Average body weight reduction in Phase 3 trials
More effective than leading GLP-1 medications
Of patients achieved clinically significant weight loss
Data from Phase 3 TRIUMPH-1 clinical trial, New England Journal of Medicine, 2024.
A new class of triple agonist that outperforms every GLP-1 medication on the market today.
No waiting rooms. No co-pays. No wasted time. RetaMD brings board-certified physicians directly to you through our secure online platform.
Complete a quick health questionnaire from the comfort of your home. Takes less than 5 minutes.
A board-certified physician reviews your profile and conducts a private virtual consultation.
If medically appropriate, your doctor prescribes Retatrutide — shipped directly and discreetly to you.
Monthly check-ins, dosage management, and 24/7 access to your care team — all online.
Takes less than 2 minutes
Join the WaitlistNo commitment required. Priority access for qualified patients.
Retatrutide is currently in Phase 3 clinical trials, with Phase 2 results published in the New England Journal of Medicine showing unprecedented efficacy.
Retatrutide simultaneously activates GIP, GLP-1, and glucagon receptors, creating a synergistic metabolic effect no single or dual agonist can replicate.
In the landmark TRIUMPH-1 study published in the New England Journal of Medicine, participants lost an average of 24.2% of body weight over 48 weeks at the highest dose.
Clinical data shows measurable improvements in HbA1c, blood pressure, triglycerides, and liver health markers, addressing the full spectrum of metabolic disease.
Join thousands of patients already on the priority waitlist.
